Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls

Journal of Neuroimmunology

Volumn 138, Issue 1-2, 2003, Pages 99-105

  Gold, Stefan M ^a   Schulz, Karl Heinz ^a   Hartmann, Sten ^a   Mladek, Mila ^a   Lang, Undine E ^b   Hellweg, Rainer ^b   Reer, Rüdiger ^c   Braumann, Klaus Michael ^c   Heesen, Christoph ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

BDNF; Exercise; Multiple sclerosis; Neuroprotection; NGF

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; STANDARDIZATION; TIME;

EID: 0038636536     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00121-8     Document Type: Article

References (43)

1. Alleva E., Santucci D. Psychosocial vs. "physical" stress situations in rodents and humans: role of neurotrophins. Physiol. Behav. 73:2001;313-320.
2. Aloe L., Bracci-Laudiero L., Alleva E., Lambiase E., Micera A., Tirassa P. Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 91:1994;10440-10444.
3. Beneke R. Anaerobic threshold, individual anaerobic threshold, and maximum lactate steady state in rowing. Med. Sci. Sports Exerc. 27:1995;863-867.
4. Besser M., Wank R. Clonally restricted production of the neurotrophins, brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J. Immunol. 162:1999;6303-6306.
5. Berchtold N.C., Kesslak J.P., Pike C.J., Adlard P.A., Cotman C.W. Estrogen and exercise interact to regulate brain-derived neurotrophic factor mRNA and protein expression in the hippocampus. Eur. J. Neurosci. 14:2001;1992-2002.
6. Bracci-Laudiero L., Aloe L., Levi-Montalcini R., Buttinelli C., Schilter D., Gillessen S., Otten U. Multiple sclerosis patients express increased levels of β-nerve growth factor in cerebrospinal fluid. Neurosci. Lett. 147:1992;9-12.
7. Casaccia-Bonnefil P., Gu C., Chao M.V. Neurotrophins in cell survival/death decisions. Adv. Exp. Med. Biol. 468:1999;275-282.
8. Cotman C.W., Berchtold N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 25:2002;295-301.
9. Dechant G., Barde Y.A. The neurotrophin receptor p75NTR: novel functions and implications for disease of the nervous system. Nat. Neurosci. 5:2002;1131-1136.
10. Ebadi M., Bashir R.M., Heidrick M.L., Hamada F.M., El Refaey H., Hamed A., Helal G., Baxi M.D., Cerutis D.R., Lassi N.K. Neurotrophins and their receptors in nerve injury and repair. Neurochem. Int. 30:1997;347-374.
11. Hadjiconstatinou M., McGuire L., Duchemin A.M., Laskowski B., Kiecolt-Glaser J., Glaser R. Changes in plasma nerve growth factor levels in older adults associated with chronic stress. J. Neuroimmunol. 116:2001;102-106.
12. Heesen C., Gold S.M., Raji A., Wiedemann K., Schulz K.H. Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis. Psychoneuroendocrinology. 27:2002;505-517.
13. Heesen C., Gold S.M., Sondermann J., Tessmer W., Schulz K.H. Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNg) release in multiple sclerosis patients and controls. J. Neuroimmunol. 132:2002;189-195.
14. Hellweg R., von Richthofen S., Anders D., Baethge C., Röpke S., Hartung H.D., Gericke C.A. The time course of nerve growth factor content in different neuropsychiatric diseases - a unifying hypothesis. J. Neural Transm. 105:1998;871-903.
15. Hellweg R., Hock C., Hartung H.D. An improved rapid and highly sensitive enzyme immunoassay for nerve growth factor. J. Methods Cell. Mol. Biol. 1:1989;43-49.
16. Hellweg R., Thomas H., Arnswald A., von Richthofen S., Kay S., Fink H., Morgenstern R., Hortnagl H. Serotonergic lesion of median raphe nucleus alters nerve growth factor content and vulnerability of cholinergic septohippocampal neurons in rat. Brain Res. 907:2001;100-108.
17. Hellweg, R., von Arnim, C.A.F., Büchner, M., Huber, R., Riepe, M.W., in press. Neuroprotection and neuronal dysfunction upon repetitive disinhibition of oxidative phosphorylation. Exp. Neurol.
18. Hoffmann-Goetz L., Pedersen B.K. Exercise and the immune system: a model of the stress response. Immunol. Today. 15:1994;283-387.
19. Hohlfeld R., Kerschensteiner M., Stadelmann C., Lassmann H., Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J. Neuroimmunol. 107:2000;161-166.
20. Kastin A.J., Pan W., Maness L.M., Banks W.A. Peptides crossing the blood-brain barrier: some unusual observations. Brain Res. 848:1999;96-100.
21. Keegan B.M., Noseworthy J.H. Multiple sclerosis. Annu. Rev. Med. 53:2002;285-302.
22. Kerschensteiner M., Gallmeier E., Behrens L., Klinkert W.E.F., Kolbeck R., Hoppe E., Oropeza-Wekerle R.L., Bartke I., Stadelmann C., Lassmann H., Wekerle H., Hohlfeld H. Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 189:1999;865-870.
23. Kurtzke J.M. Rating neurological impairment in multiple sclerosis: an expanded disability status scale. Neurology. 33:1983;1444-1452.
24. Lang U., Gallinat J., Kuhn S., Jockers-Scherübl M.C., Hellweg R. Nerve growth factor and smoking cessation. Am. J. Psychiatry. 159:2002;674-675.
25. Linker R.A., Mäurer M., Gaupp S., Martini R., Holtmann B., Giess R., Rieckmann P., Lassmann H., Toyka K.V., Sendtner M., Gold R. CNTF is a major protective factor in demyelination CNS disease: a neurotrophic cytokine as modulator of neuroinflammation. Nat. Med. 6:2002;620-624.
26. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
27. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:2000;707-717.
28. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I.R., Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5:1999;49-55.
29. Mostert S., Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception, and activity level of subjects with multiple sclerosis. Mult. Scler. 8:2002;161-168.
30. Mumford C., Compston A. Problems with rating scales for multiple sclerosis: a novel approach - the CAMBS score. J. Neurol. 240:1993;209-215.
31. Pan W., Banks W.A., Kastin A.J. Permeability of the blood-brain/spinal cord barrier to neurotrophins. Brain Res. 788:1998;87-94.
32. Petajan J.H., White A.T. Recommendations for physical activity in patients with multiple sclerosis. Sports Med. 27:1999;179-191.
33. Petajan J.H., Gappmaier E., White A.T., Spencer M., Mino L., Hicks R.W. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann. Neurol. 39:1996;432-441.
34. Poduslo J.F., Curran G.L. Permeability at the blood brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Mol. Brain Res. 36:1996;280-286.
35. Poser C.M. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
36. Rudick R., Antel J., Confavreux C., Cutter G., Ellison G., Fischer J., Lublin F., Miller A., Petkau J., Rao S., Reingold S., Syndulko K., Thompson A., Wallenberg J., Weinshenker B., Willoughby E. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann. Neurol. 42:1997;379-382.
37. Sarichielli P., Greco L., Stipa A., Floridi A., Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J. Neuroimmunol. 132:2002;180-188.
38. Schwartz M., Moalem G., Leibowitz-Amit R., Cohen I.R. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. 22:1999;295-299.
39. Skaper S.D., Pollock M., Facci L. Mast cells differentially express and release active high molecular weight neurotrophins. Brain Res. Mol. Brain Res. 97:2001;177-185.
40. Stadelmann C., Kerschensteiner M., Misgeld T., Brück W., Hohlfeld R., Lassman H. BDNF and gp145trkB in multiple sclerosis brain lesions. Neuroprotective interactions between immune cells and neuronal cells? Brain. 125:2002;75-85.
41. Torcia M., Bracci-Laudiero L., Lucibello M., Nencioni L., Labardi D., Rubatelli A., Cozzolino F., Aloe L., Garaci E. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell. 85:1996;345-356.
42. Valdo P., Stegagno C., Mazzucco S., Zuliani E., Zanusso G.L., Moretto G., Raine C.S., Bonetti B. Enhanced expression of NGF receptors in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 61:2002;91-98.
43. Villoslada P., Hauser S.L., Bartke I., Unger J., Heald N., Rosenberg D., Cheung S.W., Mobley W.C., Fisher S., Genain C.P. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the nervous system. J. Exp. Med. 191:2000;1799-1806.